



## Extension of CEO and Managing Director's Contract

**Brisbane, Australia, 19 June 2019** – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, advises that Dr Tony Keating's contract of employment as Chief Executive Officer and Managing Director has been renewed, with the existing contract due to expire on 2 July 2019. Dr Keating's fixed remuneration remains unchanged. The key terms of Dr Keating's contract of employment are set out in the annexure attached.

###

### About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies at leading hospitals in Australia and the United States have demonstrated accurate diagnosis of lower respiratory tract disease, upper respiratory tract infections, asthma/reactive airway disease, pneumonia, bronchiolitis, croup, chronic obstructive pulmonary disease and obstructive sleep apnoea. Potential customers of ResApp's products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world. For more information, please visit [www.resapphealth.com.au](http://www.resapphealth.com.au).

### Contacts

Dr Tony Keating  
CEO and Managing Director  
+61 430 180 659  
[tony@resapphealth.com.au](mailto:tony@resapphealth.com.au)

Mr Brian Leedman  
Vice President, Corporate Affairs  
+61 412 281 780  
[brian@resapphealth.com.au](mailto:brian@resapphealth.com.au)

**ResApp Health Limited** ABN 51 094 468 318

Headquarters: Level 8, 127 Creek St, Brisbane QLD 4000 Australia

Registered Office: Level 24, 44 St Georges Tce, Perth WA 6000 Australia

T +61 8 6211 5099 E [info@resapphealth.com.au](mailto:info@resapphealth.com.au) W [www.resapphealth.com.au](http://www.resapphealth.com.au)

**Annexure – Key terms of Contract of Employment for Dr Tony Keating, CEO and Managing Director**

Term	No fixed term. Contract continues until terminated in accordance with the terms of the Contract
Fixed remuneration	\$280,000 per annum, inclusive of superannuation
Other entitlements	Annual leave Incentive Options – terms as set out below
Termination notice	6 months by the individual or company
Additional provisions	Contract contains additional provisions considered standard for employment agreements of this nature

**Terms of Incentive Options**

Number of Options	975,000 Employee Incentive Options under the Company's employee share and option plan, to be issued subject to Shareholder Approval
Exercise Price	\$0.21, being a 20% premium to the 20 trading day VWAP prior to the date of the Contract, being 18 June 2019
Expiry	5 years from the date of issue
Vesting Conditions	Options issued post shareholder approval and vest on the satisfaction of the following specific performance milestones: <ul style="list-style-type: none"> <li>(i) CE Mark approval – 325,000 Options</li> <li>(ii) FDA clearance – 325,000 Options</li> <li>(iii) Commercial release of hardware product – 325,000 Options</li> </ul> <p>Dr Keating is required to be employed by the Company in order to exercise the Incentive Options</p>